Asia Pacific Human Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Type, Application (Influenza, Hepatitis, Human papilloma virus, and Others), and End User

Description

List of Tables

The Asia Pacific human vaccine adjuvants market was valued at US$ 330.19 million in 2022 and is expected to reach US$ 1,008.52 million by 2030; it is estimated to register a CAGR of 15.0% from 2022 to 2030.

Growing Pharmaceutical Industry Boosts Asia Pacific Human Vaccine Adjuvants Market

The expanding pharmaceutical industry is expected to positively influence the demand for adjuvants as they can improve the efficacy and safety of vaccines. The pharmaceutical industry's increasing focus on infectious diseases, cancer, and autoimmune disorders provides a platform for developing personalized vaccines and adjuvants targeted at these specific disease areas. This offers an opportunity for adjuvant manufacturers to develop specialized adjuvants to enhance the immune response to vaccines for these diseases. According to the EFPIA, the Brazilian, Chinese, and Indian pharmaceutical industries grew by 11.7%, 6.7%, and 11.8% during the 2016-2021 period, respectively, compared to the top five European Union markets and the US market, which recorded an average market growth of 5.8% and 5.6%, respectively. Furthermore, as per the India Brand Equity Foundation (IBEF), India is a major and rising global pharmaceutical industry player. The country is the world's largest trader of generic medications, accounting for nearly 20% of the worldwide supply by volume. It supplies ~50% of the global vaccination demand. The domestic pharmaceutical industry includes a network of 3,000 drug companies and ~10,500 manufacturing units. Based on official figures from the Indian government, the pharmaceutical sector in India is valued at nearly US$ 50 billion, of which over US$ 25 billion is derived from exports. India accounts for ~20% of the world's generic medicine exports. Further, Japan is one of the largest pharmaceutical markets in the world. According to the Ministry of Health, Labor and Welfare's (MHLW) Annual Pharmaceutical Production Statistics, the Japanese market for prescription and nonprescription pharmaceuticals in 2020 was US$ 107 billion. As the industry continues to evolve and innovate, there is an increasing demand for adjuvants that can support the development of personalized vaccines, driving significant growth and investment in the Asia Pacific human vaccine adjuvants market. Thus, the growing pharmaceutical industry worldwide will likely create lucrative growth opportunities for the Asia Pacific human vaccine adjuvants market in the coming years.

Asia Pacific Human Vaccine Adjuvants Market Overview

China has invested heavily in its healthcare and pharmaceutical industries, aiming to bolster domestic production, research, and development capabilities. This strategic focus has positioned the country as a key player in the Asia Pacific human vaccine adjuvants market. Additionally, China is among the most densely populated countries in the world; the current population is ~1.41 billion. According to the latest Global Burden of Disease (GBD) study published in October 2020, the population in the country is prone to various infectious, chronic, and acute diseases.

An increase in the prevalence of infectious diseases is expected to fuel the demand for vaccinations. According to a report by the ICO/IARC Information Centre on HPV and Cancer in 2023, China has a population of 582.4 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. About 3.8% of women in China in the general population are estimated to harbor cervical HPV-16/18 infection at a given time, and 69.1% of invasive cervical cancers are attributed to HPVs 16 or 18. Thus, the rising number of patients and the increasing demand for vaccines for treatment are also expected to boost the Asia Pacific human vaccine adjuvants market growth.

Asia Pacific Human Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Human Vaccine Adjuvants Market Segmentation

The Asia Pacific human vaccine adjuvants market is categorized into type, application, end user, and country.

Based on type, the Asia Pacific human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held the largest market share in 2022.

In terms of application, the Asia Pacific human vaccine adjuvants market is categorized into influenza, hepatitis, Human Papilloma Virus (HPV), and others. The influenza segment held the largest market share in 2022.

By end user, the Asia Pacific human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest market share in 2022.

By country, the Asia Pacific human vaccine adjuvants market is segmented into Japan, China, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific human vaccine adjuvants market share in 2022.

Croda International Plc, CSL Ltd, Dynavax Technologies Corp, Hawaii Biotech Inc, Novartis AG, Novavax Inc, Phibro Animal Health Corp, Seppic SA, and SPI Pharma Inc are some of the leading companies operating in the Asia Pacific human vaccine adjuvants market.

Product Code: BMIRE00030361

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Asia Pacific Human Vaccine Adjuvants Market - Key Market Dynamics

4.1 Asia Pacific Human Vaccine Adjuvants Market - Key Market Dynamics
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Chronic Diseases
- 4.2.2 Growing Focus on Immunization Programs
4.3 Market Restraints
- 4.3.1 Manufacturing Complexities and Regulatory Challenges
4.4 Market Opportunities
- 4.4.1 Growing Pharmaceutical Industry
4.5 Future Trends
- 4.5.1 Rising Trend of Personalized Vaccines
4.6 Impact of Drivers and Restraints:

5. Human Vaccine Adjuvants Market - Asia Pacific Market Analysis

5.1 Asia Pacific Human Vaccine Adjuvants Market Revenue (US$ Million), 2020 - 2030
5.2 Asia Pacific Human Vaccine Adjuvants Market Forecast Analysis

6. Asia Pacific Human Vaccine Adjuvants Market Analysis - by Type

6.1 Particulate Adjuvant
- 6.1.1 Overview
- 6.1.2 Particulate Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.2 Emulsion Adjuvant
- 6.2.1 Overview
- 6.2.2 Emulsion Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Combination Adjuvant
- 6.3.1 Overview
- 6.3.2 Combination Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Others
- 6.4.1 Overview
- 6.4.2 Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Human Vaccine Adjuvants Market Analysis - by Application

7.1 Influenza
- 7.1.1 Overview
- 7.1.2 Influenza: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Hepatitis
- 7.2.1 Overview
- 7.2.2 Hepatitis: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Human papilloma virus (HPV)
- 7.3.1 Overview
- 7.3.2 Human papilloma virus (HPV): Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Others
- 7.4.1 Overview
- 7.4.2 Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Human Vaccine Adjuvants Market Analysis - by End User

8.1 Pharmaceutical and Biotechnology Companies
- 8.1.1 Overview
- 8.1.2 Pharmaceutical and Biotechnology Companies: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.2 CMOs and CROs
- 8.2.1 Overview
- 8.2.2 CMOs and CROs: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Human Vaccine Adjuvants Market - Country Analysis

9.1 Asia Pacific
- 9.1.1 Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  - 9.1.1.1 China Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.1.1 China Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.1.2 China Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.1.3 China Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.2 Japan Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.2.1 Japan Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.2.2 Japan Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.2.3 Japan Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.3 India Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.3.1 India Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.3.2 India Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.3.3 India Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.4 Australia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.4.1 Australia Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.4.2 Australia Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.4.3 Australia Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.5 South Korea Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.5.1 South Korea Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.5.2 South Korea Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.5.3 South Korea Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.6 Rest of Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.6.1 Rest of Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.6.2 Rest of Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.6.3 Rest of Asia Pacific Human Vaccine Adjuvants Market Breakdown, by End User

10. Industry Landscape

10.1 Overview

11. Company Profiles

11.1 Novartis AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Dynavax Technologies Corp
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 CSL Ltd
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Seppic SA
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 SPI Pharma Inc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Hawaii Biotech Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Croda International Plc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Novavax Inc
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Phibro Animal Health Corp
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms